Eric Pujade-Lauraine, MD, PhD, discusses the prognostic factors researchers are looking for when testing patients with ovarian cancer.
Eric Pujade-Lauraine, MD, PhD
Advertisement
Articles by Eric Pujade-Lauraine, MD, PhD
Eric Pujade-Lauraine, MD, discusses the differences in testing for homologous recombination repair deficiency in patients with ovarian cancer throughout countries.
Eric Pujade-Lauraine, MD, PhD, discusses the exploratory findings from the phase III JAVELIN Ovarian 200 trial, which investigated the use of combination avelumab plus pegylated liposomal doxorubicin in patients with platinum-resistant, refractory ovarian cancer.
Advertisement
Latest Updated Articles
Differences in HRD Testing for Ovarian Cancer WorldwidePublished: March 1st 2022 | Updated:
Exploratory Analyses for JAVELIN Ovarian 200 Demonstrate Potential for Immunotherapy in Select SubgroupsPublished: June 12th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
